Limited evidence, lasting decisions: How voluntary non‐remunerated plasma donations can avoid the commercial one‐way street

MacKay, Kelsey J.; Schiltz, Fritz; Vandekerckhove, Philippe

doi:10.1111/vox.13613

Vox Sanguinis

2024

DOI: 10.1111/vox.13613

|View full text |Cite

Limited evidence, lasting decisions: How voluntary non‐remunerated plasma donations can avoid the commercial one‐way street

Kelsey J. MacKay,

Fritz Schiltz,

Philippe Vandekerckhove

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Measuring the Size of the “Third Pillar”: A Global Dataset

Schiltz,

MacKay,

Vandekerckhove

2024

The World Bank Economic Review

View full text Add to dashboard Cite

Balancing the state and the market, the “third pillar” (i.e., any association of people that is neither public nor private) is a key sector in society. In contrast to the first two pillars (the public sector and the private sector), the third pillar has received very little attention in academic and policy debates. This paper aims to facilitate research on the third pillar's relevance by constructing the first global dataset on the size of the third pillar, including estimates for 120 countries. Results show that the size of the third pillar is substantial, both when measured as third pillar time (TPT) or third pillar participation (TPP). Global TPT is equivalent to 5.1 percent of total employment, more than half of the global agricultural sector. Moreover, findings indicate that TPP equals 13.4 percent, suggesting that more than one person in eight of the world's adult population is active as a volunteer in the third pillar.

show abstract

Measuring the Size of the “Third Pillar”: A Global Dataset

Schiltz,

MacKay,

Vandekerckhove

2024

The World Bank Economic Review

View full text Add to dashboard Cite

show abstract

Generating pathways to domestically sourced plasma‐derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion

Farrugia,

Perry,

Rossi

et al. 2024

Vox Sanguinis

View full text Add to dashboard Cite

Plasma‐derived medicinal products (PDMPs) are recognized internationally as essential medicines required to treat various acute and chronic conditions including congenital deficiencies of plasma proteins in haemophilia and primary immune deficiency. Global provision of these medicines is dominated by a small number of commercial companies, influencing the price and availability of the products. Achieving a level of strategic independence from this dominance is now seen as a public health priority in many countries. During the Regional Congress of the International Society for Blood Transfusion (ISBT) in Cape Town, South Africa, in November 2023, around 50 delegates from 24 countries participated in a workshop (WS) organized jointly by the International Plasma and Fractionation Association (IPFA) and the ISBT Working Party on Global Blood Safety on pathways towards provision of PDMPs from domestic plasma independent of commercial purchase in the open market. The WS was structured around three themes, each addressed by a separate group: Quality/safety requirements for plasma for fractionation (PfF) Stepwise access for safe plasma proteins Approaching contract fractionation A synthesis of conclusions from these groups included the following: The need to acquire support from government authorities for a national plasma policy, recognizing the difficulties posed by unstable political and bureaucratic environments. The value of embedding plasma and PDMPs within a patient blood management (PBM) paradigm to promote optimal clinical use of PDMPs. Training of blood/plasma collection personnel in the relevant principles of Good Manufacturing Practice (GMP), coupled with regulatory oversight of plasma product production in the engaged jurisdictions. Appreciation that limited access to contract fractionation may necessitate a stepwise approach, which may include small‐scale preparation of versions of essential plasma proteins as an intermediate phase towards the manufacture of industrial‐scale PDMPs from domestic plasma.

show abstract

Securing commitment and control for the supply of plasma derivatives for public health systems. I: A short review of the global landscape

von Bonsdorff,

Farrugia,

Candura

et al. 2024

Vox Sanguinis

View full text Add to dashboard Cite

The social market economies of the Western world considered the provision of plasma derivatives produced from publicly owned blood services as a legitimate state commitment and, until the last decades of the 20th century, many of the relevant jurisdictions maintained state‐supported fractionation plants to convert publicly collected plasma into products for the public health system. This situation started to change in the 1990s, because of several converging factors, and currently, publicly owned/subsidized, not‐for‐profit fractionation activity has shrunk to a handful of players. However, the collection of plasma from publicly owned blood services has continued and recent developments have increased the interest of state authorities globally to increase the volume of plasma collected to increase the level of strategic independence in the supply of crucial plasma‐derived medicines from commercial market pressures, particularly the global for‐profit fractionation sector with its dominance of source plasma from paid donors in the United States. This paper reviews the development of the plasma industry and the evolution of the pressures on the supply of plasma, which has led to a situation of scarcity of key plasma‐derived medicinal products (PDMPs).

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Limited evidence, lasting decisions: How voluntary non‐remunerated plasma donations can avoid the commercial one‐way street

Cited by 4 publications

References 8 publications

Measuring the Size of the “Third Pillar”: A Global Dataset

Measuring the Size of the “Third Pillar”: A Global Dataset

Generating pathways to domestically sourced plasma‐derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion

Securing commitment and control for the supply of plasma derivatives for public health systems. I: A short review of the global landscape

Contact Info

Product

Resources

About